Intensity Therapeutics, Inc. (INTS)

Market Cap	11.63M +26.5%
Revenue (ttm)	n/a
Net Income	-10.69M
EPS	-5.82
Shares Out	2.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,766
Open	4.400
Previous Close	4.390
Day's Range	4.320 - 4.500
52-Week Range	4.320 - 43.500
Beta	3.06
Analysts	Strong Buy
Price Target	24.80 (+464.92%)
Earnings Date	May 7, 2026

About INTS

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2023
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: INTS
• Website: https://intensitytherapeutics.com

Analyst Summary

According to 5 analysts, the average rating for INTS stock is "Strong Buy." The 12-month stock price target is $24.8, which is an increase of 464.92% from the latest price.

Price Target

$24.8

(464.92% upside)

Analyst Consensus: Strong Buy